[Results and place of Fibroscan in the non-invasive diagnosis of hepatic fibrosis].
OBJECTIVE
Diagnosis of liver fibrosis by transient elastography (Fibroscan) is a new and non-invasive method. We report its results, and compare them with the non-invasive biological tests.


RESULTS
Fibroscan is validated for chronic hepatitis C, allowing to diagnose the fibrosis (Métavir) F2, F3 and F4 with areas under the ROC curve of 0.79-0.83, 0.90-0.91 and 0.91-0.97 respectively. The non-invasive diagnosis of the cirrhosis can be made with positive and negative predictive values from 70 to 95% and 77 in 95%. Preliminary data concern the HCV-HIV co-infections, primary biliary cirrhosis, NASH, portal hypertension, and the follow-up of the hepatic fibrosis. These results are altogether comparable to the various non-invasive biological tests, for cirrhosis diagnosis.


CONCLUSIONS
It's remain to determine the respective places of Fibroscan and non-invasive biological tests, in the liver fibrosis diagnosis.
Nguyen-Khac
E
E
Service d'hépatogastroentérologie, CHU d'Amiens, place Victor-Pauchet, 80054 Amiens cedex 01, France. nguyen-khac.eric@chu-amiens.fr
D004548:Elasticity; D006801:Humans; D008099:Liver / Q000473:pathology*; D008103:Liver Cirrhosis / Q000175:diagnosis* / Q000000981:diagnostic imaging / Q000473:pathology; D012372:ROC Curve; D012720:Severity of Illness Index; D014463:Ultrasonography / Q000295:instrumentation; D014732:Vibration